David Einhorn - DME Capital Management,
Holding/activity history for Teva Pharmaceutical Industries Ltd. (TEVA)
| Period | Shares | % of Portfolio | Activity | % Change to Portfolio | Reported Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026 Q1 | 2,910,729 | 2.75 | Reduce 4.84% | 0.16 | $30.12 | $87,671,158 | SEC |
| 2025 Q4 | 3,058,734 | 3.35 | Reduce 19.05% | 0.57 | $31.21 | $95,463,088 | SEC |
| 2025 Q3 | 3,778,777 | 3.00 | $20.20 | $76,331,295 | SEC | ||
| 2025 Q2 | 3,778,777 | 2.72 | Add 565.04% | 2.31 | $16.76 | $63,332,302 | SEC |
| 2025 Q1 | 568,200 | 0.44 | Add 21.27% | 0.08 | $15.37 | $8,733,234 | SEC |
| 2024 Q4 | 468,550 | 0.53 | Add 44.24% | 0.16 | $22.04 | $10,326,842 | SEC |
| 2024 Q3 | 324,850 | 0.24 | $18.02 | $5,853,797 | SEC | ||
| 2024 Q2 | 324,850 | 0.26 | $16.25 | $5,278,813 | SEC | ||
| 2024 Q1 | 324,850 | 0.21 | $14.11 | $4,583,634 | SEC |